Leaderboard
Insiders and issuers ranked by realized signed return on open-market Form 4 trades. Returns are signed: a sale followed by a rally counts against the seller.
What the metrics mean
Return - the insider's signed return per trade, averaged. A +10% stock move on a buy scores +10%; on a sell, -10%. Because most insider activity is concentrated at rallying stocks, this metric correlates with raw stock performance and doesn't fully isolate timing skill from market drift.
Edge - signed return minus the stock's average forward N-day return over the same period. An insider with +5% edge consistently chose better days to trade than someone who'd picked a random day in the same window. Isolates timing skill from "the stock just went up."
Neither metric is the same as ranking stocks by raw return - that would just surface the best-performing tickers, which you can get from any market screener.
Insiders ranked
257
Showing 50 of 257
Quality filters
10+ trades
≥3 issuers, 50% price coverage
Window
5y trailing
Trade date filter
| # | Insider | Trades | Issuers | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|---|
| 1 | Topper James N | 18/21 | 6 | 89% | +141.0% | +88.7% | +335.9% | -59.1% |
| 2 | Seidenberg Beth C | 20/23 | 4 | 95% | +129.8% | +147.9% | +166.5% | -60.2% |
| 3 | Edelman Joseph | 50/77 | 15 | 82% | +123.3% | +55.5% | +455.3% | -24.7% |
| 4 | Perceptive Advisors LLC | 50/77 | 15 | 82% | +123.3% | +55.5% | +455.3% | -24.7% |
| 5 | Perceptive Life Sciences Master Fund Ltd | 50/64 | 14 | 82% | +123.3% | +55.5% | +455.3% | -24.7% |
| 6 | Sylebra Capital LLC | 13/18 | 3 | 77% | +121.0% | +141.1% | +285.9% | -51.0% |
| 7 | Gibson Daniel Patrick | 35 | 3 | 83% | +81.6% | +77.9% | +285.9% | -54.6% |
| 8 | Akkaraju Srinivas | 36/48 | 9 | 78% | +79.0% | +31.7% | +345.3% | -40.0% |
| 9 | Cummins Wes | 47/53 | 3 | 57% | +65.6% | +18.8% | +283.6% | -58.6% |
| 10 | Demichele Michael | 36/37 | 3 | 75% | +64.5% | +36.1% | +628.1% | -23.6% |
| 11 | Mfn Partners Gp, LLC | 36/37 | 3 | 75% | +64.5% | +36.1% | +628.1% | -23.6% |
| 12 | Mfn Partners Management, LLC | 36/37 | 3 | 75% | +64.5% | +36.1% | +628.1% | -23.6% |
| 13 | Mfn Partners Management, LP | 36/37 | 3 | 75% | +64.5% | +36.1% | +628.1% | -23.6% |
| 14 | Mfn Partners, LP | 36/37 | 3 | 75% | +64.5% | +36.1% | +628.1% | -23.6% |
| 15 | Nanji Farhad | 36/37 | 3 | 75% | +64.5% | +36.1% | +628.1% | -23.6% |
| 16 | Heron Patrick J | 30/34 | 5 | 80% | +61.4% | +70.2% | +274.1% | -59.1% |
| 17 | Enright Patrick G | 11/16 | 7 | 64% | +53.3% | +26.3% | +158.2% | -81.0% |
| 18 | Whitmore Bradford T | 44/66 | 3 | 64% | +50.5% | +51.6% | +200.0% | -45.8% |
| 19 | Leonard Braden Michael | 50/88 | 10 | 54% | +48.8% | +8.5% | +249.1% | -67.9% |
| 20 | Oliver Eric L | 29/48 | 3 | 100% | +46.8% | +45.3% | +64.6% | +31.7% |
| 21 | Sylebra Capital Ltd | 25 | 3 | 76% | +46.7% | +65.5% | +119.1% | -54.6% |
| 22 | Corre Partners Management, LLC | 57/70 | 3 | 68% | +46.6% | +59.0% | +177.6% | -36.0% |
| 23 | 325 Capital LLC | 37 | 3 | 95% | +43.4% | +50.7% | +69.1% | -50.0% |
| 24 | Braner Michael David | 37 | 3 | 95% | +43.4% | +50.7% | +69.1% | -50.0% |
| 25 | Shrivastava Anil K | 37 | 3 | 95% | +43.4% | +50.7% | +69.1% | -50.0% |
| 26 | Friedberg Daniel M. | 47/48 | 4 | 91% | +41.2% | +50.7% | +71.1% | -50.0% |
| 27 | Opaleye Management Inc. | 108/192 | 9 | 56% | +40.9% | +8.8% | +469.8% | -58.1% |
| 28 | Nodelman Oleg | 30/32 | 4 | 90% | +39.6% | +40.4% | +102.2% | -19.4% |
| 29 | Horowitz Joshua | 24/27 | 4 | 71% | +37.9% | +10.0% | +136.2% | -26.7% |
| 30 | Biotechnology Value Fund II LP | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 31 | Biotechnology Value Fund L P | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 32 | Bvf Gp Holdings LLC | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 33 | Bvf I Gp LLC | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 34 | Bvf II Gp LLC | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 35 | Bvf Inc/Il | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 36 | Bvf Partners L P/Il | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 37 | Bvf Partners Os Ltd. | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 38 | Biotechnology Value Trading Fund Os LP | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 39 | Lampert Mark N | 59/90 | 7 | 68% | +37.0% | +15.2% | +178.3% | -49.6% |
| 40 | Icahn Carl C | 114/117 | 6 | 96% | +33.6% | +19.3% | +127.7% | -10.8% |
| 41 | Martin William C | 23 | 3 | 83% | +32.4% | +40.7% | +62.2% | -6.2% |
| 42 | Bradsher Neal C | 160/194 | 3 | 79% | +32.1% | +36.0% | +88.7% | -33.2% |
| 43 | Broadwood Capital Inc | 160/194 | 3 | 79% | +32.1% | +36.0% | +88.7% | -33.2% |
| 44 | Broadwood Partners, L.P. | 160/194 | 3 | 79% | +32.1% | +36.0% | +88.7% | -33.2% |
| 45 | Landes Joshua | 83/91 | 3 | 84% | +31.5% | +28.5% | +71.2% | -12.5% |
| 46 | Obus Nelson | 83/91 | 3 | 84% | +31.5% | +28.5% | +71.2% | -12.5% |
| 47 | Wynnefield Capital Inc | 83/91 | 3 | 84% | +31.5% | +28.5% | +71.2% | -12.5% |
| 48 | Wynnefield Capital Management LLC | 83/91 | 3 | 84% | +31.5% | +28.5% | +71.2% | -12.5% |
| 49 | Wynnefield Partners Small Cap Value LP | 83/91 | 3 | 84% | +31.5% | +28.5% | +71.2% | -12.5% |
| 50 | Wynnefield Partners Small Cap Value LP I | 83/91 | 3 | 84% | +31.5% | +28.5% | +71.2% | -12.5% |
Showing 1-50 of 257